CATB Catabasis Pharmaceuticals, Inc.

1.33
-0.03  -2%
Previous Close 1.36
Open 1.35
Price To book 1.14
Market Cap 29.89M
Shares 22,470,000
Volume 176,697
Short Ratio 1.00
Av. Daily Volume 1,937,610

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a did not meet primary endpoint - June 2016
CAT-2054
Hypercholesterolemia
Phase 1/2 Part B top-line data released January 31, 2017 - endpoint not met. Part C data due in 2017, with an interim update in 2Q.
CAT-1004
Duchenne muscular dystrophy (DMD)

Latest News

  1. J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021
  2. Edited Transcript of CATB earnings conference call or presentation 11-May-17 8:30pm GMT
  3. Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth
  4. Catabasis Pharmaceuticals posts 1Q loss
  5. Catabasis Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Business Progress
  6. Investor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call
  7. Catabasis Pharmaceuticals to Report First Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, May 11
  8. Catabasis Pharmaceuticals Announces Favorable Results for Functional Assessments in the MoveDMD® Trial for Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting
  9. Catabasis Pharmaceuticals to Present at the American Academy of Neurology 69th Annual Meeting
  10. Edited Transcript of CATB earnings conference call or presentation 16-Mar-17 8:30pm GMT
  11. Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Highlights
  12. Catabasis Pharmaceuticals to Present at Oppenheimer’s 27th Annual Healthcare Conference
  13. Sarepta's DMD Drug Launch Slow; What's in Store for 2017?
  14. Catabasis Pharmaceuticals to Present at the 2017 Muscular Dystrophy Association Scientific Conference
  15. Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Developments on Thursday, March 16
  16. Catabasis Pharmaceuticals to Present at Cowen and Company 37th Annual Health Care Conference
  17. Catabasis Pharmaceuticals Announces Promotion of Ted Hibben to Chief Business Officer
  18. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Catabasis Pharmaceuticals, Inc.
  19. Catabasis Hits 52-Week Low on Poor DMD Drug Study Data
  20. Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data